COLUMBUS, Ohio, April 14, 2008 (PRIME NEWSWIRE) -- Stonefly Communications Group, an inVentiv Health company (Nasdaq:VTIV) and a purpose-driven healthcare advertising agency, recently won a five-year agency of record assignment from Patheon, a leading global provider of drug development and manufacturing services to pharmaceutical, biotech and specialty pharmaceutical companies.
Stonefly will be responsible for strategic marketing and creative brand development for the company. The details of the contract were not disclosed.
"Patheon has built a solid reputation in the drug development, contract manufacturing and packaging business," said John Racik, President and CEO of Stonefly Communications Group. "This is a competitive market, and we are confident that Stonefly's experience and understanding will help continue putting Patheon at the forefront of this industry for years to come. We are happy and excited to be a part of the team."
"We are thrilled about working with Stonefly," said Terence S. Novak, President, North American Operations and Chief Global Marketing Officer of Patheon. "Their extensive experience and deep understanding of marketing to the pharmaceutical and biotech industries will allow us to successfully communicate how Patheon can find the most rapid, cost-effective route to move their molecules from development to commercialization. We look forward to partnering with them."
About Patheon, Inc.
Patheon Inc. is the leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to more than 270 of the world's leading pharmaceutical and biotechnology companies. Our services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, Liquid-Filled Hard Capsules and a variety of modified release technologies.
Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take you direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic programs can accelerate your early phase development project to clinical trials while minimizing the consumption of your valuable API.
Patheon's integrated development and manufacturing network of 12 sites, with locations across North America and Europe, ensures that your product can be launched with confidence anywhere in the world.
Patheon (TSX:PTI) (www.patheon.com)
About Stonefly Communications Group
Stonefly Communications Group is a purpose-driven healthcare advertising agency dedicated to redefining success for its clients around the world. With a promise to continually innovate, Stonefly's client advisors and creative champions develop actionable strategies that engage audiences with bold strategic, tactical and creative solutions. For more information on Stonefly, visit www.stoneflygroup.com
About inVentiv Health
inVentiv Health (Nasdaq:VTIV) is the leading provider of commercialization and complementary services to the healthcare industry globally. inVentiv delivers its customized clinical, sales, marketing and communications solutions through its four core business segments: inVentiv Clinical, inVentiv Communications, inVentiv Commercial and inVentiv Patient Outcomes. inVentiv Health's client roster is comprised of more than 325 leading pharmaceutical, biotech, life sciences and healthcare payor companies, including the top 20 global pharmaceutical manufacturers. For more information, visit www.inventivhealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by inVentiv Health, Inc. with the Securities and Exchange Commission for further discussion of these and other factors.